Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Bronchodilators Market

Bronchodilators Market Share

Report ID: GMI9421
Published Date: May 2024
Report Format: PDF

Download Free Sample

Bronchodilators Market Share

The bronchodilators industry is competitive in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel products with improved efficiency are key market strategies for bronchodilators manufacturers, driving competition and innovation in the industry. This emphasis on innovation aims to address evolving clinical needs and enhance patient outcomes, positioning companies to gain market share and meet the growing demand for advanced bronchodilators.

Bronchodilators Companies

Some of the eminent market participants operating in the bronchodilators industry include:

AstraZeneca
Boehringer Ingelheim International GmbH
Cipla Inc.
GlaxoSmithKline plc
Glenmark Pharmaceuticals Limited
Innoviva
Medline Plus
Merck & Co.,
Mylan N.V.
Novartis AG
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The bronchodilators market size was valued at USD 30.7 billion in 2023 and is estimated to grow at 4.9% CAGR from 2024 to 2032, owing to the increasing prevalence of respiratory disorders, such as asthma and COPD.

The anticholinergic drugs segment in the market reached USD 9.9 billion in 2023, driven by the effectiveness in managing bronchospasms.

North America bronchodilators market size was USD 11 billion in 2023, attributed to rising air pollution, smoking, and a geriatric population.

Boehringer Ingelheim International GmbH, Cipla Inc., GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Innoviva, Medline Plus, Merck & Co., Mylan N.V., Novartis AG, Sun Pharmaceutical Industries Ltd and Teva Pharmaceutical Industries Ltd.